{"id":99976,"date":"2023-09-11T08:45:24","date_gmt":"2023-09-11T08:45:24","guid":{"rendered":"https:\/\/dailytalks.org\/?p=99976"},"modified":"2023-09-11T08:45:24","modified_gmt":"2023-09-11T08:45:24","slug":"bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=99976","title":{"rendered":"Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU"},"content":{"rendered":"<p>Berlin, February 6, 2023 \u2013 Bayer has submitted an application for market authorization to the European Medicines Agency (EMA) for aflibercept 8 mg in two major retinal eye diseases, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).The submission is based on positive data from the phase III study&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin, February 6, 2023 \u2013 Bayer has submitted an application for market authorization to the<\/p>\n","protected":false},"author":1,"featured_media":99977,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-99976","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/99976-bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/99976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=99976"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/99976\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/99977"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=99976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=99976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=99976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}